Clinical Research Directory
Browse clinical research sites, groups, and studies.
Activated Charcoal Use in Chronic Kidney Disease Patients
Sponsor: Mansoura University
Summary
Hyperphosphatemia management is initially based on restricting dietary phosphorus intake. Hyperphosphatemia is almost always seen in patients on dialysis and may contribute to progressive vascular calcification. Considering that activated charcoal is generally well-tolerated and may have a favorable side effect profile compared to conventional phosphate binders, it presents a promising alternative. Until now, no clinical trial has primarily investigated the effect of activated charcoal on hyperphosphatemia in dialysis patients.
Official title: Efficacy and Safety of Activated Charcoal on Mineral Bone Disorder in Chronic Kidney Disease Patients
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2025-08
Completion Date
2025-11
Last Updated
2025-08-08
Healthy Volunteers
No
Conditions
Interventions
Activated Charcoal
oral activated charcoal capsules
Phosphate Binders
calcium-based or non-calcium based (sevelamer) binders
Locations (1)
Urology and Nephrology Center
Al Mansurah, Please Select, Egypt